



Sample Information

Patient Name: 魏可吟
Gender: Male
ID No.: A101603748
History No.: 41468375
Age: 71

Ordering Doctor: DOC3160J 羅永鴻
Ordering REQ.: D6BPAHP
Signing in Date: 2021/07/22

Path No.: S110-99145
MP No.: F21059
Assay: Oncomine Focus Assay
Sample Type: FFPE
Block No.: S110-76683A
Percentage of tumor cells: 40%

Reporting Doctor: DOC5466K 葉奕成 (Phone: 8#5466)

Note:

Sample Cancer Type: Other Solid Tumor

Table of Contents	Page
Variant Details	1
Biomarker Descriptions	2

Report Highlights
0 Relevant Biomarkers
0 Therapies Available
0 Clinical Trials

Relevant Biomarkers

No relevant biomarkers found in this sample.

Prevalent cancer biomarkers without relevant evidence based on included data sources

KIT p.(D820G) c.2459A>G

Variant Details

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
KIT	p.(D820G)	c.2459A>G	COSM1316	chr4:55599333	37.75%	NM_000222.3	missense	2000
JAK1	p.(P733=)	c.2199A>G	.	chr1:65310489	49.75%	NM_002227.4	synonymous	1998
PDGFRA	p.(G313=)	c.939T>G	.	chr4:55133726	51.05%	NM_006206.6	synonymous	1998
PDGFRA	p.(V824=)	c.2472C>T	.	chr4:55152040	47.35%	NM_006206.6	synonymous	2000

Variant Details (continued)

DNA Sequence Variants (continued)

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
FGFR4	p.(P136L)	c.407C>T	.	chr5:176517797	99.66%	NM_213647.3	missense	1480
EGFR	p.(Q787=)	c.2361G>A	.	chr7:55249063	17.33%	NM_005228.5	synonymous	1085
RET	p.(S904=)	c.2712C>G	.	chr10:43615633	49.25%	NM_020975.6	synonymous	670

Biomarker Descriptions

KIT (KIT proto-oncogene, receptor tyrosine kinase)

Background: The KIT gene, also known as CD117, encodes the KIT proto-oncogene receptor tyrosine kinase (c-KIT), a member of the PDGF receptor type III receptor tyrosine kinase family, which includes PDGFRA, PDGFRB, CSF1R, FLT1, FLT3, FLT4 and KDR^{1,2}. KIT is a receptor for stem cell factor, important in regulating growth and development of hematopoietic cells³. The KIT gene is flanked by the PDGFRA and KDR genes on chromosome 4q12. Ligand binding to KIT results in kinase activation and stimulation of downstream pathways including the RAS/RAF/MEK/ERK and PI3K/AKT/MTOR pathways promoting cell proliferation and survival⁴.

Alterations and prevalence: Recurrent somatic KIT alterations are observed in both solid and hematological cancers and include activating mutations such as single nucleotide variants, small duplications, and complex in-frame insertions or deletions (indels). Mutations in KIT exons 8, 9, 11, and 17 disrupt auto-inhibitory mechanisms and lead to constitutive activity⁵. Gain of function mutations are found in up to 70% of mast cell tumors, 17% of nasal T-cell lymphomas, and 9% of dysgerminoma⁶. Somatic mutations in exon 11 occur in 60-70% of all gastrointestinal stromal tumor (GIST), whereas alterations in exons 8 and 17 are more common in myeloid cancers^{5,6,7}. A common kinase domain mutation that causes ligand-independent constitutive activation, D816V, occurs in 80-93% of aggressive forms of mastocytosis^{8,9}.

Potential relevance: Imatinib¹⁰ (2001) is approved for KIT positive malignant GIST and adult patients with aggressive systemic mastocytosis (SM) harboring D816V mutations. Imatinib is also recommended for KIT activating mutations in melanoma and exon 9 and 11 mutations in GIST^{11,12,13}. Mutations in exon 17 have been identified to confer resistance to imatinib and sunitinib¹⁴. Patients with acute myeloid leukemia (AML) that harbor KIT activating mutations with t(8;21) and inv(16) have an increased risk of relapse¹⁵. KIT D816V mutation is associated with the diagnosis of SM and aggressiveness of the disease^{16,17}.

Clinical Trials in Taiwan region:

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. Ségaliny et al. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. *J Bone Oncol.* 2015 Mar;4(1):1-12. PMID: 26579483
2. Berenstein. Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis. *Biomark Insights.* 2015;10(Suppl 3):1-14. PMID: 26309392
3. Ashman. The biology of stem cell factor and its receptor C-kit. *Int. J. Biochem. Cell Biol.* 1999 Oct;31(10):1037-51. PMID: 10582338
4. Cardoso et al. The SCF/c-KIT system in the male: Survival strategies in fertility and cancer. *Mol. Reprod. Dev.* 2014 Dec;81(12):1064-79. PMID: 25359157
5. Abbaspour et al. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. *Drug Des Devel Ther.* 2016;10:2443-59. PMID: 27536065
6. Liang et al. The C-kit receptor-mediated signal transduction and tumor-related diseases. *Int. J. Biol. Sci.* 2013;9(5):435-43. PMID: 23678293
7. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
8. Garcia-Montero et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. *Blood.* 2006 Oct 1;108(7):2366-72. PMID: 16741248
9. Chatterjee et al. Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. *Oncotarget.* 2015 Jul 30;6(21):18250-64. PMID: 26158763
10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf
11. NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 2.2021]
12. NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2021]
13. Casali et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 2018 Oct 1;29(Supplement_4):iv68-iv78. PMID: 29846513
14. KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions. *Cancer Res.* 2016 Nov 1;76(21):6140-6142. PMID: 27803101
15. NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 3.2021]
16. Lim et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood.* 2009 Jun 4;113(23):5727-36. PMID: 19363219
17. Verstovsek. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. *Eur. J. Haematol.* 2013 Feb;90(2):89-98. PMID: 23181448